Headquartered in Osaka, Japan, MTPC focuses on several therapeutic areas, including immunology and inflammation, vaccines, central nervous system (CNS), diabetes and metabolic disease and employs over 5,000 people globally.

In a statement, Bain said that the independent company plans significant investment in innovation, both internal product development and external licensing and acquisitions.

As an independent company, Tanabe Pharma will continue to build on its legacy of medical innovation while developing new opportunities for growth through business development, licensing activities, enhanced R&D productivity, commercialization and strategic acquisitions.

“Tanabe Pharma has been delivering innovative medicines to Japanese patients for centuries, and we are proud to partner with MTPC and support its next phase of growth and evolution,” said Masa Suekane, a partner and head of Japan Healthcare, Industrials and Financial Services at Bain.”

“We believe there are promising signs for growth and untapped opportunities in Japan’s life sciences industry as government and regulators have launched several initiatives to accelerate the development and approval of innovative medicines in the Japanese market,” said Ricky Sun, a partner at Bain Capital Life Sciences. “This is an exciting opportunity to leverage our team’s clinical insights and company creation support to build out a scale platform focused on long-term fundamental drug development in areas of significant unmet need to ultimately bring transformative medicines to patients in Japan and globally.”

The transaction is expected to close in the third quarter of 2025 and is subject to customary closing conditions, regulatory clearance and shareholder approvals.